ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727 IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1 non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Recurrent Or Progressive Low-grade Gliomas (lggs)
-
Age: Between 2 years - 25 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Patients must be progressive or recurrent after having been treated with at least one prior tumor-directed therapy before enrollment.
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
- Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2.
You may not be eligible for this study if the following are true:
-
- Patients must not have had progressive disease while on therapy with vinblastine or a MEK inhibitor.
- Patients with diffuse intrinsic pontine tumors as seen on MRI (> 2/3 of pons involvement on imaging) are not eligible even if biopsy reveals grade I/II histology.
- Patients may not be receiving any other investigational agents.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.